^
Association details:
| Biomarker: | HER-2 P780ins |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activating HER2 mutations in HER2 gene amplification negative breast cancer
Published date:
12/07/2012
Excerpt:
Seven of these mutations are activating mutations, including G309A, D769H, D769Y, V777L, P780ins, V842I, and R896C...L755S produced lapatinib resistance, but was not an activating mutation in our experimental systems. All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.
DOI:
10.1158/2159-8290.CD-12-0349
